Benjamin Palleiko Sells 3,322 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 3,322 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $26.71, for a total transaction of $88,730.62. Following the transaction, the chief executive officer directly owned 466,375 shares in the company, valued at approximately $12,456,876.25. The trade was a 0.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $26.76 on Friday. The company’s 50 day moving average is $20.20 and its 200 day moving average is $16.65. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $26.85. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -6.77 and a beta of -0.12.

Wall Street Analyst Weigh In

Several research firms have issued reports on KALV. HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $37.00 to $27.00 in a report on Friday, May 1st. Stifel Nicolaus lifted their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Needham & Company LLC lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Finally, Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $30.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KALV. Parallel Advisors LLC lifted its position in KalVista Pharmaceuticals by 45.8% during the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 589 shares during the period. BNP Paribas Financial Markets lifted its position in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in KalVista Pharmaceuticals during the third quarter valued at $55,000. Wolverine Asset Management LLC acquired a new position in KalVista Pharmaceuticals during the third quarter valued at $57,000. Finally, KLP Kapitalforvaltning AS acquired a new position in KalVista Pharmaceuticals during the third quarter valued at $63,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.